Risk assessment and management of post-transplant diabetes mellitus

Eugene Han, Myoung Soo Kim, YuSeun Kim, Eun Seok Kang

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

The success rate of organ transplantation has been increasing with advances in surgical and pharmacological techniques. However, the number of solid organ transplant recipients who require metabolic disease management is also growing. Post-transplant diabetes mellitus (PTDM) is a common complication after solid organ transplantation and is associated with risks of graft loss, cardiovascular morbidity, and mortality. Other risk factors for PTDM include older age, genetic background, obesity, hepatitis C virus infection, hypomagnesemia, and use of immunosuppressant agents (corticosteroids, calcineurin inhibitors, and mammalian target of rapamycin inhibitor). Management of PTDM should be started before the transplantation plan to properly screen high-risk patients. Even though PTDM management is similar to that of general type 2 diabetes, therapeutic approaches must be made with consideration of drug interactions between immunosuppressive agents, glucose-lowering medications, and graft rejection and function.

Original languageEnglish
Pages (from-to)1559-1569
Number of pages11
JournalMetabolism: Clinical and Experimental
Volume65
Issue number10
DOIs
Publication statusPublished - 2016 Oct 1

Fingerprint

Risk Management
Diabetes Mellitus
Transplants
Organ Transplantation
Immunosuppressive Agents
Metabolic Diseases
Graft Rejection
Virus Diseases
Sirolimus
Disease Management
Drug Interactions
Hepacivirus
Type 2 Diabetes Mellitus
Adrenal Cortex Hormones
Obesity
Transplantation
Pharmacology
Morbidity
Glucose
Mortality

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Han, Eugene ; Kim, Myoung Soo ; Kim, YuSeun ; Kang, Eun Seok. / Risk assessment and management of post-transplant diabetes mellitus. In: Metabolism: Clinical and Experimental. 2016 ; Vol. 65, No. 10. pp. 1559-1569.
@article{250dd7d13be8443e8ac848d9638ad069,
title = "Risk assessment and management of post-transplant diabetes mellitus",
abstract = "The success rate of organ transplantation has been increasing with advances in surgical and pharmacological techniques. However, the number of solid organ transplant recipients who require metabolic disease management is also growing. Post-transplant diabetes mellitus (PTDM) is a common complication after solid organ transplantation and is associated with risks of graft loss, cardiovascular morbidity, and mortality. Other risk factors for PTDM include older age, genetic background, obesity, hepatitis C virus infection, hypomagnesemia, and use of immunosuppressant agents (corticosteroids, calcineurin inhibitors, and mammalian target of rapamycin inhibitor). Management of PTDM should be started before the transplantation plan to properly screen high-risk patients. Even though PTDM management is similar to that of general type 2 diabetes, therapeutic approaches must be made with consideration of drug interactions between immunosuppressive agents, glucose-lowering medications, and graft rejection and function.",
author = "Eugene Han and Kim, {Myoung Soo} and YuSeun Kim and Kang, {Eun Seok}",
year = "2016",
month = "10",
day = "1",
doi = "10.1016/j.metabol.2016.07.011",
language = "English",
volume = "65",
pages = "1559--1569",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "10",

}

Risk assessment and management of post-transplant diabetes mellitus. / Han, Eugene; Kim, Myoung Soo; Kim, YuSeun; Kang, Eun Seok.

In: Metabolism: Clinical and Experimental, Vol. 65, No. 10, 01.10.2016, p. 1559-1569.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Risk assessment and management of post-transplant diabetes mellitus

AU - Han, Eugene

AU - Kim, Myoung Soo

AU - Kim, YuSeun

AU - Kang, Eun Seok

PY - 2016/10/1

Y1 - 2016/10/1

N2 - The success rate of organ transplantation has been increasing with advances in surgical and pharmacological techniques. However, the number of solid organ transplant recipients who require metabolic disease management is also growing. Post-transplant diabetes mellitus (PTDM) is a common complication after solid organ transplantation and is associated with risks of graft loss, cardiovascular morbidity, and mortality. Other risk factors for PTDM include older age, genetic background, obesity, hepatitis C virus infection, hypomagnesemia, and use of immunosuppressant agents (corticosteroids, calcineurin inhibitors, and mammalian target of rapamycin inhibitor). Management of PTDM should be started before the transplantation plan to properly screen high-risk patients. Even though PTDM management is similar to that of general type 2 diabetes, therapeutic approaches must be made with consideration of drug interactions between immunosuppressive agents, glucose-lowering medications, and graft rejection and function.

AB - The success rate of organ transplantation has been increasing with advances in surgical and pharmacological techniques. However, the number of solid organ transplant recipients who require metabolic disease management is also growing. Post-transplant diabetes mellitus (PTDM) is a common complication after solid organ transplantation and is associated with risks of graft loss, cardiovascular morbidity, and mortality. Other risk factors for PTDM include older age, genetic background, obesity, hepatitis C virus infection, hypomagnesemia, and use of immunosuppressant agents (corticosteroids, calcineurin inhibitors, and mammalian target of rapamycin inhibitor). Management of PTDM should be started before the transplantation plan to properly screen high-risk patients. Even though PTDM management is similar to that of general type 2 diabetes, therapeutic approaches must be made with consideration of drug interactions between immunosuppressive agents, glucose-lowering medications, and graft rejection and function.

UR - http://www.scopus.com/inward/record.url?scp=84981214786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84981214786&partnerID=8YFLogxK

U2 - 10.1016/j.metabol.2016.07.011

DO - 10.1016/j.metabol.2016.07.011

M3 - Review article

VL - 65

SP - 1559

EP - 1569

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 10

ER -